Schering Korea to launch injectable testosterone for male climacterics.

Published: 2005-06-28 06:55:00

Updated: 2005-06-28 06:55:00

Schering Korea has launched Nebido, an injectable testosterone hormone for the male climacteric syndrome, administering once every 3 month to keep a normal blood level of testosterone to eliminate any possible roller coaster effect that might be raised with other common hormone therapy.

Most o...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK